title: 1,25-Dihydroxyvitamin D3 stimulates both alkaline phosphatase gene transcription and mRNA stability in human bone cells.
abstract: We have previously reported that 1,25(OH)2D3 stimulated the cellular alkaline phosphatase (ALP) activity and increased the steady-state level of ALP mRNA in a human osteosarcoma cell line (TE-85), under serum-free conditions. To define the molecular mechanism by which 1,25(OH)2D3 acts to stimulate ALP activity, the time courses of the increases in ALP activity and in the steady-state ALP mRNA level in response to 1,25(OH)2D3 were evaluated. 1,25(OH)2D3 progressively increased the steady-state level of ALP mRNA from 5 to 24 h of treatment, at which time a plateau was observed. In contrast, no significant increase in ALP-specific activity was detected until after 10 h of treatment, at which time the activity increased linearly with time up to 72 h. These time courses are consistent with the premise that the increased ALP activity was the result of increased gene expression. Nuclear runoff analysis indicated that the transcription rate of the ALP gene was more than five-fold higher in the 1,25(OH)2D3-treated cells than in the control cells. In addition, it was found that 1,25(OH)2D3 treatment increased ALP mRNA stability. The 1,25(OH)2D3-induced increase in ALP mRNA stability was not due to an interaction of the 1,25(OH)2D3-receptor complex with the ALP mRNA, since the removal of 1,25(OH)2D3 did not abolish its stabilizing effect. In the presence of cycloheximide, the stabilizing effect of 1,25(OH)2D3 was abolished, suggesting that a 1,25(OH)2D3-inducible protein factor was involved. Based on these findings, we have proposed a model in which 1,25(OH)2D3 stimulated ALP activity in human bone cells through mechanisms involving both (1) increased transcription of the ALP gene and (2) increased stability of ALP mRNA, an effect which requires the de novo synthesis of a protein, a putative ALP mRNA "stabilizing factor."
authors.affiliation: Department of Biochemistry, Loma Linda University, California.
authors.forename: E
authors.initials: E
authors.lastname: Kyeyune-Nyombi
authors.forename: K H
authors.initials: KH
authors.lastname: Lau
authors.forename: D J
authors.initials: DJ
authors.lastname: Baylink
authors.forename: D D
authors.initials: DD
authors.lastname: Strong
mesh_terms: D000469:Alkaline Phosphatase / Q000235:genetics*; D001842:Bone and Bones / Q000201:enzymology*; D002117:Calcitriol / Q000494:pharmacology*; D002460:Cell Line / Q000187:drug effects; D015342:DNA Probes; D004004:Dichlororibofuranosylbenzimidazole / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D014176:Protein Biosynthesis / Q000187:drug effects; D012333:RNA, Messenger / Q000302:isolation & purification*; D013997:Time Factors; D014158:Transcription, Genetic / Q000187:drug effects*
chemical_list: D015342:DNA Probes; D012333:RNA, Messenger; D004004:Dichlororibofuranosylbenzimidazole; D000469:Alkaline Phosphatase; D002117:Calcitriol